Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
- PMID: 17676050
- DOI: 10.1038/nm1620
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
Abstract
Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis (MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-beta, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of T(H)2 cells and CD4+CD25+FoxP3+ regulatory T cells (T(reg)) independent of antigen specificity. Type II monocyte-induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed T(H)17 cell development and promoted both T(H)2 differentiation and expansion of T(reg) cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.
Similar articles
-
Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. J Autoimmun. 2014. PMID: 24934599 Review.
-
Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis.Scand J Immunol. 2011 Sep;74(3):235-243. doi: 10.1111/j.1365-3083.2011.02575.x. Scand J Immunol. 2011. PMID: 21595733
-
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. CNS Drugs. 2011. PMID: 21476611 Free PMC article. Review.
-
Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.Exp Neurol. 2011 Jan;227(1):19-23. doi: 10.1016/j.expneurol.2010.10.009. Epub 2010 Oct 20. Exp Neurol. 2011. PMID: 20969865 Free PMC article.
-
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.PLoS One. 2012;7(3):e33797. doi: 10.1371/journal.pone.0033797. Epub 2012 Mar 30. PLoS One. 2012. PMID: 22479444 Free PMC article.
Cited by
-
Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models.Mediators Inflamm. 2016;2016:8489251. doi: 10.1155/2016/8489251. Epub 2016 Mar 13. Mediators Inflamm. 2016. PMID: 27034594 Free PMC article. Review.
-
Alternatively activated macrophages in spinal cord injury and remission: another mechanism for repair?Mol Neurobiol. 2013 Jun;47(3):1011-9. doi: 10.1007/s12035-013-8398-6. Epub 2013 Jan 16. Mol Neurobiol. 2013. PMID: 23321790 Review.
-
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.Cytokine. 2015 Jun;73(2):236-44. doi: 10.1016/j.cyto.2015.01.009. Epub 2015 Mar 17. Cytokine. 2015. PMID: 25794663 Free PMC article. Review.
-
Myeloid cells - targets of medication in multiple sclerosis.Nat Rev Neurol. 2016 Sep;12(9):539-51. doi: 10.1038/nrneurol.2016.110. Epub 2016 Aug 12. Nat Rev Neurol. 2016. PMID: 27514287 Review.
-
Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet.Neurotherapeutics. 2007 Oct;4(4):661-5. doi: 10.1016/j.nurt.2007.07.007. Neurotherapeutics. 2007. PMID: 17920547 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
